Drug Trial Radar · NCT06216392
Phase III Study of GR1802 Injection in Patients With Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Jan 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
450
Planned (sponsor's estimate)
Start
Jan 2024
Primary completion
Jun 2025
Study completion Jan 2026
Sponsor
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of GR1802 injection in comparison to placebo in patients with atopic dermatitis. Patients will receive GR1802 injection or Placebo every 2 Weeks.
Conditions
- Atopic Dermatitis
Interventions
GR1802 injectionBiological
150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
placeboBiological
0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving EASI-75 at week 16Time frame: at Week 16
- Proportion of subjects with IGA score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline at week 16Time frame: at Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.